Evidence map›Paper›PMID 30664427›Full record

ArticleTurkish thoracic journal2019

Repeated Thrombolytic Treatment for Recurrent Pulmonary Thromboembolism: A Report of 2 Cases and a Literature Review.

Emine Argüder, Ebru Parlak, Habibe Hezer, Ayşegül Karalezli, H Canan Hasanoğlu

Abstract read
In one paragraph

Article in Turkish thoracic journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Emine ArgüderDepartment of Chest Diseases, Ankara Yıldırım Beyazıt University School of Medicine, Ankara, Turkey.ORCID https://orcid.org/0000-0002-4769-9328
Ebru ParlakClinic of Chest Diseases, Ankara Atatürk Training and Research Hospital, Ankara, Turkey.ORCID https://orcid.org/0000-0002-2901-7645
Habibe HezerClinic of Chest Diseases, Ankara Atatürk Training and Research Hospital, Ankara, Turkey.ORCID https://orcid.org/0000-0002-5373-8629
Ayşegül KaralezliDepartment of Chest Diseases, Ankara Yıldırım Beyazıt University School of Medicine, Ankara, Turkey.ORCID https://orcid.org/0000-0003-3013-4061
H Canan HasanoğluDepartment of Chest Diseases, Ankara Yıldırım Beyazıt University School of Medicine, Ankara, Turkey.ORCID https://orcid.org/0000-0002-8051-433X
Ankara University · TRAnkara Atatürk Eğitim ve Araştırma Hastanesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present 2 cases of pulmonary thromboembolism (PTE). The first case, a 50-year-old man, was admitted to the emergency department because of sudden onset dyspnea and left side chest pain. He was diagnosed with intermediate-risk (submassive) PTE, and thrombolytic treatment was commenced. The patient fully recovered, but 5 days later, he was diagnosed with a new, high-risk PTE. The second patient, a 23-year-old woman, presented with syncope, dyspnea, and chest pain for 2 days. She was diagnosed with high-risk (massive) PTE. Thrombolytic treatment was commenced, and the patient fully recovered, too. But the later patient was also diagnosed with a new PTE 4 days later. We applied repeated thrombolytic treatment in the patients due to repeated PTE. The first patient fully recovered and was discharged from the hospital, but the second patient died because of gastrointestinal bleeding and renal insufficiency. A repeated thrombolytic treatment could be an alternative treatment for these patients, considering treatment's risks.

Identifiers

PMID30664427
PMCPMC6340683
OpenAlexW2897542317

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.